Upstream Bio Funding & Investors
Waltham, MA
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. They are clinical-stage monoclonal antibodies that inhibit the TSLP receptor, a validated target located upstream of various signaling cascades that influence a range of immune cells that are important in common and unusual illnesses.
upstreambio.comTotal Amount Raised: $408,000,000
Upstream Bio Funding Rounds
Series B
$200,000,000
Series B Investors
Enavate SciencesVenrock Healthcare Capital PartnersOmega Fund ManagementTCG Crossover ManagementOrbiMed AdvisorsAltshuler ShahamSamsara BiocapitalHBM Healthcare InvestmentsDecheng CapitalBain Capital Life SciencesWellington ManagementAccess IndustriesHBM PartnersSeries A
$8,000,000
Series A Investors
HBM PartnersSeries A
$200,000,000
Series A Investors
Maruho Co.OrbiMed AdvisorsSamsara BiocapitalDecheng CapitalTCG Crossover ManagementAltshuler ShahamAccess IndustriesOmega Fund ManagementHBM Healthcare Investments
Funding info provided by Diffbot.